Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sugarman

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2018
Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy SubjectsSanna Rosengren, Jennifer Souratha, Dave Conway, et al.
American Journal of Obstetrics and Gynecology|November 22, 2001
Attitudes of maternal-fetal specialists concerning maternal-fetal surgeryA D Lyerly, R C Cefalo, M Socol, et al.
Electrophoresis|March 1, 1990
Synergistic induction of polypeptides by tumor necrosis factor and interferon-gamma in cells sensitive or resistant to tumor necrosis factor: assessment by computer based analysis of two-dimensional gels using the PDQUEST systemM H Beresini, B J Sugarman, H M Shepard, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 1991
Regulation of c-fos and c-jun protooncogene expression by the Ca(2+)-ATPase inhibitor thapsigarginA Schönthal, J Sugarman, J H Brown, et al.
The American Journal of Medicine|January 1, 1990
Hypertension and reversible myocardial depression associated with autologous bone marrow transplantationJ Sugarman, T M Bashore, E M Ohman, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1986
Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophagesJ L Urban, H M Shepard, J L Rothstein, et al.
Plos One|July 22, 2021
Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancerDavid W Kang, Beate Bittner, Barry J Sugarman, et al.
AIDS Research and Human Retroviruses|July 20, 1997
Scientific, logistical, and ethical issues related to creation of a stem cell repository for use in experimental trials of gene therapy for AIDSJ K Fraser, J Sugarman, P R McCurdy, et al.
Tropical and Geographical Medicine|October 1, 1992
Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in TanzaniaC S Dukes, J Sugarman, J P Cegielski, et al.
The Journal of Clinical Ethics|January 1, 1996
Professional healthcare workers' attitudes toward treating patients with multidrug-resistant tuberculosisJ Sugarman, P Terry, R R Faden, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 15, 2018
Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy SubjectsSanna Rosengren, Jennifer Souratha, Dave Conway, et al.
American Journal of Obstetrics and Gynecology|November 22, 2001
Attitudes of maternal-fetal specialists concerning maternal-fetal surgeryA D Lyerly, R C Cefalo, M Socol, et al.
Electrophoresis|March 1, 1990
Synergistic induction of polypeptides by tumor necrosis factor and interferon-gamma in cells sensitive or resistant to tumor necrosis factor: assessment by computer based analysis of two-dimensional gels using the PDQUEST systemM H Beresini, B J Sugarman, H M Shepard, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 1991
Regulation of c-fos and c-jun protooncogene expression by the Ca(2+)-ATPase inhibitor thapsigarginA Schönthal, J Sugarman, J H Brown, et al.
The American Journal of Medicine|January 1, 1990
Hypertension and reversible myocardial depression associated with autologous bone marrow transplantationJ Sugarman, T M Bashore, E M Ohman, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 1986
Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophagesJ L Urban, H M Shepard, J L Rothstein, et al.
Plos One|July 22, 2021
Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancerDavid W Kang, Beate Bittner, Barry J Sugarman, et al.
AIDS Research and Human Retroviruses|July 20, 1997
Scientific, logistical, and ethical issues related to creation of a stem cell repository for use in experimental trials of gene therapy for AIDSJ K Fraser, J Sugarman, P R McCurdy, et al.
Tropical and Geographical Medicine|October 1, 1992
Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in TanzaniaC S Dukes, J Sugarman, J P Cegielski, et al.
The Journal of Clinical Ethics|January 1, 1996
Professional healthcare workers' attitudes toward treating patients with multidrug-resistant tuberculosisJ Sugarman, P Terry, R R Faden, et al.
Pageof 13